Crinetics Pharmaceuticals Stock (NASDAQ: CRNX)

Crinetics Pharmaceuticals

CRINETICS PHARMACEUTICALS IN

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Woman,Pharmacist,Wearing,Lab,Coat,Carefully,Selects,Medication,In,A

Analyst Color

Biotech

News

Health Care

Analyst Ratings

General

CRNX

JP Morgan&#39;s survey of endocrinologists finds strong awareness of Crinetics&#39; atumelnant, with positive efficacy impressions. Analysts see long-term potential.

JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics&#39; Atumelnant Data

Test,Tube,Row.,Concept,Of,Medical,Or,Science,Laboratory,,Liquid

Initiation

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

Markets

Trading Ideas

ASMB

AVTX

CWEN

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

Press Releases

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Management

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Earnings

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Amicus Therapeutics

ImmunityBio

Immunovant

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Comments

Crinetics Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga